Helix BioPharma Corp. announced earnings results for the third quarter ended April 30, 2021. For the third quarter, the company announced operating loss was CAD 2.584 million compared to CAD 2.385 million a year ago. Net loss was CAD 2.554 million compared to CAD 2.489 million a year ago. Basic loss per share was CAD 0.02 compared to CAD 0.02 a year ago. For the nine months, operating loss was CAD 6.875 million compared to CAD 6.587 million a year ago. Net loss was CAD 5.268 million compared to CAD 6.896 million a year ago. Basic loss per share was CAD 0.04 compared to CAD 0.05 a year ago. Basic loss per share from continuing operations was CAD 0.05 compared to CAD 0.05 a year ago.